In Q3 of fiscal 2026, the quarter ended Sep 27, 2026, Quidelortho Corp reported revenue of $618.9 million, down 11.6% from the same quarter a year earlier. It recorded a net loss of $53.8 million. The operating loss came to $7.5 million, an operating margin of -1.2%. Diluted earnings per share were -$0.78.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 27, 2026
|
Q3 FY2026
Sep 27, 2026
|
Q2 FY2026
Jun 28, 2026
|
Q1 FY2026
Mar 29, 2026
|
Q4 FY2025
Dec 28, 2025
|
Q3 FY2025
Sep 28, 2025
|
Q2 FY2025
Jun 29, 2025
|
Q1 FY2025
Mar 30, 2025
|
Q4 FY2024
Dec 29, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2,593
-4.5%
|
619
-11.6%
|
631
+2.8%
|
620
-10.5%
|
724
+2.2%
|
700
-3.7%
|
614
-3.6%
|
693
-2.6%
|
708
-4.7%
|
| Research and development |
182
-3.1%
|
42
+2.4%
|
49
+6.6%
|
45
-15.6%
|
46
-3.2%
|
42
-25.8%
|
46
-18.8%
|
53
-10.1%
|
47
-20.2%
|
| Selling, general and administrative |
766
+3.6%
|
183
-2.2%
|
190
+6.6%
|
199
+6.6%
|
194
+3.7%
|
187
+0.3%
|
178
-5.4%
|
187
-8.6%
|
188
-0.1%
|
| Operating income |
-127
+86.6%
|
-8
+98.9%
|
-22
+87.9%
|
-32
-197.5%
|
-66
+34.0%
|
-705
-4798.7%
|
-181
-53.8%
|
33
+101.9%
|
-100
-350.4%
|
| Interest expense |
212
|
55
+20.2%
|
55
+35.1%
|
51
+27.8%
|
51
|
46
|
40
|
40
|
—
|
| Other non-operating income (expense) |
4
+134.0%
|
0
+100.0%
|
-5
+44.0%
|
3
+342.9%
|
5
+4800.0%
|
-1
+0.0%
|
-8
-90.9%
|
-1
+26.3%
|
0
+100.8%
|
| Pretax income |
-336
+70.4%
|
-63
+91.7%
|
-81
+64.6%
|
-80
-803.4%
|
-112
+20.2%
|
-757
-2528.1%
|
-230
-40.9%
|
-9
+99.5%
|
-141
-1431.5%
|
| Income tax |
33
-23.3%
|
-9
+61.9%
|
12
-54.7%
|
12
+215.4%
|
18
-51.2%
|
-24
-168.5%
|
26
+269.7%
|
4
+104.2%
|
38
+331.5%
|
| Net income |
-369
+68.7%
|
-54
+92.7%
|
-93
+63.6%
|
-92
-622.8%
|
-131
+26.7%
|
-733
-3583.4%
|
-255
-72.9%
|
-13
+99.3%
|
-178
-2648.6%
|
| Basic EPS |
-5.40
+69.0%
|
-0.78
+92.8%
|
-1.36
+63.9%
|
-1.35
-610.5%
|
-1.92
+27.4%
|
-10.78
-3493.3%
|
-3.77
-71.4%
|
-0.19
+99.3%
|
-2.64
-2622.2%
|
| Diluted EPS |
-5.40
+69.0%
|
-0.78
+92.8%
|
-1.36
+63.9%
|
-1.35
-610.5%
|
-1.92
+27.4%
|
-10.78
-3493.3%
|
-3.77
-71.4%
|
-0.19
+99.3%
|
-2.64
-2622.2%
|
| Weighted average shares, basic |
68
+1.0%
|
69
+1.0%
|
68
+0.9%
|
68
+1.0%
|
68
+0.9%
|
68
+1.0%
|
68
+0.9%
|
68
+0.9%
|
67
+1.0%
|
| Weighted average shares, diluted |
68
+1.0%
|
69
+1.0%
|
68
+0.9%
|
68
+1.0%
|
68
+0.9%
|
68
+1.0%
|
68
+0.9%
|
68
+0.9%
|
67
+1.0%
|
| Other measures | |||||||||
| Depreciation and amortization |
462
+5.2%
|
120
+6.7%
|
117
+5.8%
|
113
+5.4%
|
112
+2.9%
|
112
-0.9%
|
110
-5.0%
|
107
-6.8%
|
109
-5.3%
|
| EBITDA |
334
+165.0%
|
112
+118.9%
|
95
+234.8%
|
81
-41.9%
|
46
+419.1%
|
-593
-562.7%
|
-70
-4928.6%
|
140
+108.5%
|
9
-94.3%
|
| Interest coverage |
-0.60x
|
-0.14x
|
-0.40x
|
-0.62x
|
-1.30x
|
-15.29x
|
-4.46x
|
0.81x
|
—
|
| Margins | |||||||||
| Operating margin |
-4.91%
|
-1.21%
|
-3.46%
|
-5.13%
|
-9.16%
|
-100.70%
|
-29.43%
|
4.71%
|
-14.18%
|
| Pretax margin |
-12.96%
|
-10.16%
|
-12.87%
|
-12.83%
|
-15.53%
|
-108.14%
|
-37.40%
|
-1.27%
|
-19.91%
|
| Profit margin |
-14.24%
|
-8.69%
|
-14.72%
|
-14.81%
|
-18.06%
|
-104.73%
|
-41.60%
|
-1.83%
|
-25.20%
|
| EBITDA margin |
12.89%
|
18.11%
|
15.04%
|
13.08%
|
6.38%
|
-84.68%
|
-11.47%
|
20.16%
|
1.26%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- QDEL (Nasdaq)
- Fiscal year ends
- January 1
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1906324
- Former names
- Coronado Topco, Inc. (until Apr 11, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.